SENATE No.

The Commonwealth of Massachusetts

PRESENTED BY:

Cynthia Stone Creem

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:

An Act clarifying chapter 111L - biotechnology.

PETITION OF:

NAME:

Cynthia Stone Creem

DISTRICT/ADDRESS:

First Middlesex and Norfolk

The Commonwealth of Massachusetts

In the Year Two Thousand and Nine

AN ACT CLARIFYING CHAPTER 111L - BIOTECHNOLOGY.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1

-	
2	SECTION 1. Paragraph (c) of Section 1 of Chapter 111L of the General Laws as appearing in the 2006
3	Official Edition, is hereby amended by striking in lines 15-16 the words "placental and umbilical cord
4	cells and human adult stem cells", and inserting at the end of this same paragraph the following
5	sentence:
6	
7	"Nothing in this chapter shall prohibit research or clinical applications involving human adult
8	stem cells, umbilical cord cells, amniotic fluid cells or placental cells."
9	
10	
11	SECTION 2. Section 2 of Chapter 111L of the General Laws as appearing in the 2006 Official
12	Edition, is hereby amended by striking the definition of "Donated to research" in lines 7-14 and
13	inserting in place thereof the following:
14	
15	". "Donated to research", when, in the absence of valuable consideration and after
16	fulfillment of the requirements of informed consent, the persons from whose gametes or
17	cells the pre-implantation embryo has originated or will originate gives the pre-
18	implantation embryo, gametes or cells to another person; provided, however, that the
19	recipient shall not transfer the extant or resultant pre-implantation embryo to a uterus or
20	uterine-like environment or nurture the pre-implantation embryo beyond 14 days of
21	development.'
22	

SECTION 3. Said Section 2 is hereby further amended by inserting the following newdefinitions:

25

25	
26	"ESCRO committee", means an Embryonic Stem Cell Research
27	Oversight committee that is constituted and operated in a manner
28	consistent with the guidelines of either the National Academies of
29	Sciences or the International Society for Stem Cell Research.'
30	
31	"Reasonable costs", for purposes of reimbursing oocyte donors, may
32	include, but are not limited to, any of the following types of costs if
33	approved by an institutional review board: travel, temporary lodging,
34	childcare, medical care, health insurance (if limited to co-pays and
35	deductibles and the purchase of time-limited accident insurance coverage
36	for complications arising directly from the egg donation process) and
37	actual lost wages, and any other types of such costs as may be approved
38	by such institutional review board.'
39	
40	SECTION 4. Said Section 2 is further amended by striking the definition of "Valuable
41	consideration" in lines 90-93 and replacing it with the following:
42	
43	"Valuable consideration", any consideration beyond reimbursement for reasonable costs
44	incurred in connection with the donation, removal, processing, disposal, preservation,
45	quality control or storage of gametes or embryos for research purposes."
46	
47	
48	SECTION 5. Section 3(a) of Chapter 111L of the General Laws as appearing in the 2006
49	
49 50	Official Edition, shall be deleted and new language inserted as follows:
	Official Edition, shall be deleted and new language inserted as follows:
50	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of
50 51 52	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research,
50 51	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created
50 51 52 53	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer,
50 51 52 53 54 55	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and
50 51 52 53 54	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer,
50 51 52 53 54 55 56 57	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and
50 51 52 53 54 55 56 57 58	Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted."
50 51 52 53 54 55 56 57 58 59	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006
50 51 52 53 54 55 56 57 58 59 60	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006 Official Edition, shall be amended by inserting in line 9 after the words "duly authorized"
50 51 52 53 54 55 56 57 58 59 60 61	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006
50 51 52 53 54 55 56 57 58 59 60 61 62	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006 Official Edition, shall be amended by inserting in line 9 after the words "duly authorized institutional review board" the following:
50 51 52 53 54 55 56 57 58 59 60 61 62 63	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006 Official Edition, shall be amended by inserting in line 9 after the words "duly authorized institutional review board" the following: "or ESCRO committee; provided that if such research is approved only by an ESCRO
50 51 52 53 54 55 56 57 58 59 60 61 62 63 64	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006 Official Edition, shall be amended by inserting in line 9 after the words "duly authorized institutional review board" the following: "or ESCRO committee; provided that if such research is approved only by an ESCRO committee, documentation shall be maintained by the ESCRO committee that an
50 51 52 53 54 55 56 57 58 59 60 61 62 63	 Official Edition, shall be deleted and new language inserted as follows: "Research and clinical applications involving the derivation and use of human embryonic stem cells from materials donated to research, including, without limitation, pre-implantation embryos, whether created by the method of fertilization or by somatic cell nuclear transfer, parthenogenesis or other asexual means, gametes, somatic cells and parthenotes shall be permitted." SECTION 6. Section 3 (b) of Chapter 111L of the General Laws as appearing in the 2006 Official Edition, shall be amended by inserting in line 9 after the words "duly authorized institutional review board" the following: "or ESCRO committee; provided that if such research is approved only by an ESCRO

67 68	in section 2 or in a manner permitted under the laws of the state or foreign country where the donation to research occurred and in a manner otherwise acceptable to the ESCRO."
69	
70 71	And said section 3 (b) is further, by inserting in lines 9-10 after the words "approval of the institutional review board", the following: "or ESCRO committee".
72	institutional review board, the following. Of ESERO committee.
73	And further, by inserting in line 13 after the words "permanent record by the board", the
74	following: "or ESCRO committee".
75	
76	And further, by inserting in line 14 after the words "for which the board", the following: "or
77	ESCRO committee".
78	
79	
80	SECTION 7. Section 8(c) of Chapter 111L of the General Laws as appearing in the 2006
81 82	Official Edition, shall be amended by deleting in lines 12- 13 the words: "or cadaveric tissue";
82 83	and by inserting in line 17 after the words "regulate the use" the following: "or study"
83 84	SECTION 8. Section 9(e) of Chapter 111L of the General Laws as appearing in the 2006
85	Official Edition, shall be amended by deleting all language following the words "not less than
86	twice a year"; and by inserting language as follows:
87	
88	"Notwithstanding section 11A 1/2 of chapter 30A of the General Laws,
89	the council may conduct its meetings by telephone conference or similar
90	communications equipment which allows all persons participating in the
91	meeting to hear each other at the same time. Participation by such means
92	shall constitute presence in person at a meeting. Notice of a meeting held
93	in this manner shall be provided in accordance with the requirements of
94 05	section 11A 1/2 of chapter 30A of the General Laws, and shall state that
95 96	members of the public will be afforded a location, as specified in the notice, where they may attend the meeting by conference telephone or
90 97	similar communications equipment."
98	similar communications equipment.
99	
100	SECTION 9. Section 10(f) of Chapter 111L of the General Laws as appearing in the 2006
101	Official Edition, shall be amended by deleting all language after the words "and (ii)" in line 74
102	and inserting the following language:
103	
104	" provides documentation to the department demonstrating that the institution has either
105	an institutional review board or ESCRO committee or both, or provides a copy of a
106	contract between the institution and either a private or public institutional review board or
107 108	ESCRO committee, as applicable, which shall provide any review required by this chapter. Any institution which submits an application and meets the requirements for a
108 109	certificate of registration pursuant to this section shall not have the certificate of
109	registration unreasonably withheld. A certificate may be withheld if the department
111	determines that the applicant institution has violated subsection (m)."

112	
113	
114	SECTION 10. Section 10(i) of Chapter 111L of the General Laws as appearing in the 2006
115	Official Edition, shall be amended by deleting all language following the words "pursuant to
116	subsection (f)" and inserting the following language:
117	
118	"shall submit an annual report to the department providing a summary of the human
119	embryonic stem cell research approved during each calendar year pursuant to section 3(b)
120	of this chapter and a statement representing that such research was reviewed in
121	accordance with this chapter, if applicable."
122	
123	SECTION 11. In Section 10(n), subsection (2) shall be deleted in its entirety, and the following
124	language inserted as follows:
125	
126	"(2) The department may, after an opportunity for an adjudicatory
127	proceeding conducted pursuant to chapter 30A, upon determination that an
128	institution conducting research pursuant to this chapter has violated this
129	subsection undertake the following actions:
130	
131	(i) for the violation of clause (iii) of paragraph (n)(1), revoke or refuse to
132	renew such certificate of registration or assess upon the holder a civil
133	administrative penalty not to exceed \$250,000 and may require the holder
134	to submit to additional oversight as a condition or retention, or future
135	consideration of reinstatement of the certificate of registration;
136	
137	(ii) for a violation of clause (i), (ii), (iv), (vi) or (vii) of paragraph (n)(1),
138	assess upon the holder a civil administrative penalty not to exceed
139	\$100,000; or
140	
141	(iii) for a first violation of clause (v) of paragraph (n)(1) censure a holder;
142	and for each subsequent violation of said clause (v) of said paragraph
143	(n)(1), suspend such certificate of registration until compliance with
144	subsection (i), and impose a civil administrative penalty, as determined by
145	the department not to exceed \$1,000."
146	
147	
148	